Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies. As the known oncomir, miR-17∼92, is regulated by BCR-ABL fusion in chronic myeloid leukaemia, we in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Scherr, M, Elder, A, Battmer, K, Barzan, D, Bomken, S, Ricke-Hoch, M, Schröder, A, Venturini, L, Blair, H J, Vormoor, J, Ottmann, O, Ganser, A, Pich, A, Hilfiker-Kleiner, D, Heidenreich, O, Eder, M
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3948162/
https://ncbi.nlm.nih.gov/pubmed/24280866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.361
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars